Biomarker Partnering Terms and Agreements -





 Publication date: April 2014 | Version: 7 | Pages: 998

 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in biomarker partnering deals
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers

 

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 700 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading biomarker deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                            

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009. The chapter is organized by specific biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

 

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

  

 Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

  

 Biomarker Partnering Terms and Agreements includes:

 

  • Trends in biomarker dealmaking in the biopharma industry since 2009
  • Analysis of biomarker deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biomarker deals
  • Access to several biomarker contract documents
  • The leading biomarker deals by value since 2009
  • Most active biomarker dealmakers since 2009
  • The leading biomarker partnering resources

 

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise biomarker rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


 

 

   

 

TABLE OF CONTENTS 

 

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in biomarker dealmaking 

  

2.1. Introduction

2.2. Biomarker partnering over the years

2.3. Big pharma biomarker dealmaking activity

2.4. Most active biomarker dealmakers

2.5. Biomarker partnering by deal type

2.6. Biomarker partnering by disease type

2.7. Biomarker partnering by stage of development

2.8 Average deal terms for biomarkers

2.8.1 Biomarker headline values

2.8.2 Biomarker upfront payments

2.8.3 Biomarker milestone payments

2.8.4 Biomarker royalty rates

2.9. The anatomy of biomarker partnering

2.9. The anatomy of a biomarker deal

2.9.a. Case study 1: Kinemed, GlaxoSmithKline- June 2012

2.9.b. Case study 2: Roche, Rules-based Medicine, Psynova Neurotech- December 2009 

 

Chapter 3 – Leading biomarker deals 

 

3.1. Introduction

3.2. Top biomarker deals by value

3.3. Top biomarker deals involving big pharma 

 

Chapter 4 – Big pharma biomarker deals 

 

4.1. Introduction

4.2. How to use big pharma biomarker partnering deals

4.3. Big pharma biomarker partnering company profiles

Abbott

Amgen

AstraZeneca

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Eisai

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Kyowa Hakko Kirin

Merck & Co

Merck KGaA

Novartis

Novo Nordisk

Pfizer

Purdue

Roche

Sanofi

Servier

Takeda

Teva

 

Chapter 5 – Biomarker contracts dealmaking directory 

 

5.1. Introduction

5.2. By Company A-Z

Abbott Laboratories

Adamis Pharmaceuticals

ADMA Biologics

Altair Nanotechnologies

Amarantus BioSciences

ARCA Biopharma

Arno Therapeutics

Arrayit 139

Arrayit Diagnostics

Avalon Pharmaceuticals

BG Medicine

Biogen Idec

Biotage

Caliper Life Sciences

Celera

Clinical Data

Columbia University

DeCODE Genetics

DiagnoCure

Enterome Bioscience

Galmed Pharmaceuticals

Gen-Probe

Genzyme

Genzyme Genetics

GlaxoSmithKline

Guided Therapeutics

Health Discovery

Intrexon

Inverness Medical Innovations

Invivis Pharmaceuticals

KineMed

Konica Minolta

Laboratory Corporation of America

Merck and Co

Novartis

Perugia University

Power3 Medical Products

Psynova Neurotech

Quest Diagnostics

Regulus Therapeutics

Response Genetics

Roche

Rules-Based Medicine

Sanofi

Skyline Diagnostics

The Regents of the University of California

Transgenomic

TrovaGene

University of Cambridge

University of Cincinnati

US Army

Wayne State University

Zora Biosciences

5.3. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Contract service

Development

Distribution

Equity purchase

Licensing

Manufacturing

Marketing

Option

Promotion

Research

Supply

5.4. By therapy area

Cardiovascular

Central Nervous System

Genetic disorders

Metabolic

Musculoskeletal

Oncology

Respiratory

 

Chapter 6 – Biomarker dealmaking by technology type 

 

6.1. Introduction

6.2. Deals by biomarker type

Biomarkers

 

Chapter 7 – Biomarker partnering resource center 

  

7.1. Online biomarker partnering

7.2. Biomarker partnering events

7.3. Further reading on biomarker dealmaking

 

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

Order Form – Therapy Reports

 

Table of figures 

  

Figure 1: Biomarker partnering since 2009

Figure 2: Big pharma – top 50 – biomarker deals 2009 to 2014

Figure 3: Big pharma biomarker deal frequency – 2009 to 2014

Figure 4: Active biomarker dealmaking activity– 2009 to 2014

Figure 5: Biomarker partnering by deal type since 2009

Figure 6: Biomarker partnering by disease type since 2009

Figure 7: Biomarker partnering by oncology target since 2009

Figure 8: Biomarker partnering by deal type since 2009

Figure 9: Biomarker deals with a headline value

Figure 10: Biomarker deal headline value distribution, US$million – 2009-2014– Discovery stage

Figure 11: Biomarker deal headline value distribution, US$million – 2009-2014 – preclinical stage

Figure 12: Biomarker deal headline value distribution, US$million – 2009-2014– phase I stage

Figure 13: Biomarker deal headline value distribution, US$million – 2009-2014– phase II stage

Figure 14: Biomarker deal headline value distribution, US$million – 2009-2014– phase III stage

Figure 15: Biomarker deal headline value distribution, US$million – 2009-2014– regulatory stage

Figure 16: Biomarker deal headline value distribution, US$million – 2009-2014– marketed stage

Figure 17: Summary median headline value by stage of development, 2009-2014

Figure 18: Biomarker deals with an upfront value

Figure 19: Biomarker deal upfront value distribution, US$million – 2009-2014– discovery stage

Figure 20: Biomarker deal upfront value distribution, US$million – 2009-2014– preclinical stage

Figure 21: Biomarker deal upfront value distribution, US$million – 2009-2014– phase I stage

Figure 22: Biomarker deal upfront value distribution, US$million – 2009-2014– phase II stage

Figure 23: Biomarker deal upfront value distribution, US$million – 2009-2014– phase III stage

Figure 24: Biomarker deal upfront value distribution, US$million – 2009-2014– regulatory stage

Figure 25: Biomarker deal upfront value distribution, US$million – 2009-2014– marketed stage

Figure 26: Summary median headline value by stage of development, 2009-2014

Figure 27: Biomarker deals with a milestone value

Figure 28: Biomarker deal milestone value distribution, US$million – 2009-2014– discovery stage

Figure 29: Biomarker deal milestone value distribution, US$million – 2009-2014– preclinical stage

Figure 30: Biomarker deal milestone value distribution, US$million – 2009-2014– phase I stage

Figure 31: Biomarker deal milestone value distribution, US$million – 2009-2014– phase II stage

Figure 32: Biomarker deal milestone value distribution, US$million – 2009-2014– phase III stage

Figure 33: Biomarker deal milestone value distribution, US$million – 2009-2014– regulatory stage

Figure 34: Biomarker deal milestone value distribution, US$million – 2009-2014– marketed stage

Figure 35: Biomarker deals with a royalty rate value

Figure 36: Biomarker deal royalty rate value distribution, US$million – 2009-2014– discovery stage

Figure 37: Biomarker deal royalty rate value distribution, US$million – 2009-2014– preclinical stage

Figure 38: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase I stage

Figure 39: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase II stage

Figure 40: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase III stage

Figure 41: Biomarker deal royalty rate value distribution, US$million – 2009-2014– regulatory stage

Figure 42: Biomarker deal royalty rate value distribution, US$million – 2009-2014– marketed stage

Figure 43: Summary median headline value by stage of development, 2009-2014

Figure 44: Components of the typical biomarker deal structure

Figure 44: Top biomarker deals by value since 2009

Figure 45: Top biomarker deals signed by big pharma value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events